Last checked at 5 Apr 2024 11:39
Renalytix plc
("Renalytix" or the "Company")
Change of Registered Address
LONDON and SALT LAKE CITY, April 5, 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimising clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that the Company's registered address has changed to 2 Leman Street, London, United Kingdom, E1W 9US.
For further information, please contact:
Renalytix plc | www.renalytix.com | |
James McCullough, CEO | Via Walbrook PR | |
|
| |
Stifel (Nominated Adviser, Joint Broker) | Tel: 020 7710 7600 | |
Alex Price / Nicholas Moore / Nick Harland / Samira Essebiyea |
| |
|
| |
Investec Bank plc (Joint Broker) | Tel: 020 7597 4000 | |
Gary Clarence / Shalin Bhamra |
| |
|
| |
Walbrook PR Limited | Tel: 020 7933 8780 or renalytix@walbrookpr.com | |
Paul McManus / Alice Woodings | Mob: 07980 541 893 / 07407 804 654 | |
|
| |
CapComm Partners |
| |
Peter DeNardo | Tel: 415-389-6400 or investors@renalytix.com | |
About Renalytix
Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.